| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Novavax (NASDAQ:NVAX) with a Overweight rating and announc...
HC Wainwright & Co. analyst Sean Lee maintains Novavax (NASDAQ:NVAX) with a Buy and raises the price target from $10 to ...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
- SEC 13D/ Amended Filing
Reports $220 Million in Aircraft SalesNovavax, Inc. (NASDAQ:NVAX) has completed the transfer of the marketing authorization for...
GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration an...
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secret...